Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deferred Tax Liability (2019 - 2020)

Historic Non-Current Deferred Tax Liability for Silence Therapeutics (SLN) over the last 2 years, with Q4 2020 value amounting to $33011.3.

  • Silence Therapeutics' Non-Current Deferred Tax Liability rose 698.01% to $33011.3 in Q4 2020 from the same period last year, while for Dec 2020 it was $33011.3, marking a year-over-year increase of 698.01%. This contributed to the annual value of $32103.7 for FY2020, which is 476.29% up from last year.
  • As of Q4 2020, Silence Therapeutics' Non-Current Deferred Tax Liability stood at $33011.3, which was up 698.01% from $30857.4 recorded in Q4 2019.
  • In the past 5 years, Silence Therapeutics' Non-Current Deferred Tax Liability ranged from a high of $33011.3 in Q4 2020 and a low of $30857.4 during Q4 2019